Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Bischof, Lara  [Clear All Filters]
2022
Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LKatharina, Backhaus D, Brauer D, Goldmann K, Franke G-N, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2022.
Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke G-N, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission. Blood Adv. 2022.
Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, Merz M, Vucinic V, Franke G-N, Herling M, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12(12):170.
2023
Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, et al. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Leukemia. 2023.
2024
Schwind S, Bischof L, Bill M, Grimm J, Ussmann J, Backhaus D, Brauer D, Thanh TPham, Merz M, Franke G-N, et al. Quantifying MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?. Hemasphere. 2024;8(3):e55.